BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Acquired by Royal Bank of Canada

Royal Bank of Canada increased its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 3.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,391 shares of the company’s stock after purchasing an additional 2,399 shares during the quarter. Royal Bank of Canada owned 0.06% of BeOne Medicines worth $20,905,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ONC. BNP Paribas Financial Markets lifted its holdings in BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the period. SEB Asset Management AB acquired a new position in shares of BeOne Medicines during the 1st quarter worth $16,653,000. Renaissance Technologies LLC acquired a new position in shares of BeOne Medicines during the 1st quarter worth $19,438,000. Capital International Sarl increased its holdings in shares of BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares in the last quarter. Finally, Slow Capital Inc. increased its holdings in shares of BeOne Medicines by 51.5% in the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after purchasing an additional 9,280 shares in the last quarter. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Trading Up 1.4%

Shares of BeOne Medicines stock opened at $327.53 on Thursday. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The business has a 50 day moving average price of $294.53 and a 200 day moving average price of $308.67. The company has a market capitalization of $35.94 billion, a P/E ratio of 73.27 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on ONC shares. Truist Financial boosted their price objective on shares of BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Morgan Stanley reiterated an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Citizens Jmp reissued a “market outperform” rating and set a $396.00 price target on shares of BeOne Medicines in a research note on Wednesday, July 1st. Nomura upgraded BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Finally, Leerink Partners raised their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $394.00.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
• Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
• Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
• Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $323.69, for a total transaction of $337,932.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $312.71, for a total value of $361,805.47. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 345,561 shares of company stock valued at $105,625,947 over the last three months. Insiders own 6.19% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.